预测癌症相关静脉血栓栓塞的临床-遗传风险评分:基于两个独立前瞻性队列的开发与验证研究
该研究利用西班牙ONCOTHROMB 12-01队列364例门诊癌症患者数据,结合9个遗传变异、肿瘤部位、TNM分期和BMI>25 kg/m²构建ONCOTHROMB评分,并在维也纳癌症与血栓研究队列263例患者中验证。ONCOTHROMB评分预测6个月内VTE的AUC优于Khorana评分。
要点
- ONCOTHROMB评分包含9个遗传变异、肿瘤部位、TNM分期和BMI>25 kg/m²。
- 开发队列中ONCOTHROMB评分AUC 0.781 vs Khorana评分0.580(P < .001)。
- 验证队列中ONCOTHROMB评分AUC 0.720 vs Khorana评分0.561(P < .0001)。
核心结论
- ONCOTHROMB评分同时纳入临床和遗传变量,较Khorana评分能更好地识别可能从初级血栓预防中获益的门诊癌症患者。
研究设计与样本
- 研究为开发与验证研究,开发队列为西班牙ONCOTHROMB 12-01人群364例门诊患者,验证队列为维也纳癌症与血栓研究人群263例患者。
- 开发队列在诊断时收集与VTE风险相关的临床数据(包括Khorana评分),并对51个已知与VTE相关的遗传变异进行基因分型。
- 采用多变量逻辑回归确定每个遗传和临床变量与VTE风险的权重,构建ONCOTHROMB评分。
- 通过受试者工作特征曲线下面积(AUC)、校准和需治疗患者数比较ONCOTHROMB评分与Khorana评分。
主要发现
- 9个遗传变异、肿瘤部位、TNM分期和BMI>25 kg/m²与VTE相关,用于构建ONCOTHROMB评分。
- 开发队列中ONCOTHROMB评分预测总体VTE风险的AUC为0.781,Khorana评分为0.580(P < .001)。
- 验证队列中相同肿瘤类型患者的ONCOTHROMB评分AUC为0.686,Khorana评分为0.577(P < .001)。
- 验证队列中所有肿瘤类型患者的ONCOTHROMB评分AUC为0.720,Khorana评分为0.561(P < .0001)。
临床怎么用
- 原文结论指出ONCOTHROMB评分较Khorana评分能更好地识别可能从初级血栓预防中获益的门诊癌症患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving chemotherapy, but its accuracy in identifying patients at high risk has been questioned. The aim of this study was to develop and validate a clinical-genetic score that improves the assessment of VTE risk in oncology outpatients within 6 months of diagnosis. METHODS: The new score was developed using the data of 364 outpatients belonging to the Spanish ONCOTHROMB 12-01 population. In this cohort, clinical data associated with the risk of VTE were collected at the time of diagnosis, including the Khorana score. These patients were also genotyped for the 51 genetic variants known to be associated with VTE. Multivariate logistic regression was performed to determine the weight of each genetic and clinical variable in relation to VTE risk, allowing a clinical-genetic risk score (the ONCOTHROMB score) to be developed. The Khorana and the ONCOTHROMB scores were then compared via the area under the receiver operating characteristic curve (AUC), calibration, and the number of patients needed to treat. The new score was then validated in a study of 263 patients in the Vienna Cancer and Thrombosis Study population. RESULTS: Nine genetic variants, tumor site, TNM stage, and a body mass index of > 25 kg/m2 were found to be associated with VTE and were used to build the ONCOTHROMB score, which better predicted the overall risk of VTE than did the Khorana score (AUC, 0.781 v 0.580; P < .001). Similar AUC results were recorded in the validation study the Vienna Cancer and Thrombosis Study cohort involving patients with the same type of tumor (AUC for the ONCOTHROMB score v the Khorana score: 0.686 v 0.577; P < .001) and with all type of tumors (AUC for the ONCOTHROMB score v the Khorana score: 0.720 v 0.561; P < .0001). CONCLUSION: The ONCOTHROMB score for VTE risk in outpatients with cancer, which takes into account both clinical and genetic variables, better identifies patients who might benefit from primary thromboprophylaxis than does the Khorana score.
引用
- Muñoz A, Ay C, Grilz E, et al. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. J Clin Oncol. 2023. PMID: 36730884. doi:10.1200/JCO.22.00255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。